AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CRISPR Therapeutics AG Director's Dealing 2018

Jun 16, 2018

30936_dirs_2018-06-15_d0368c7d-6068-4008-a9cc-883cc9e32af0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CRISPR Therapeutics AG (CRSP)
CIK: 0001674416
Period of Report: 2018-06-15

Reporting Person: KASINGER JAMES R. (General Counsel and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-06-15	Stock Option (Right to Buy)	$59.31	A	32000	Acquired	2028-06-15	Common Shares (32000)	Direct

Footnotes

F1: This option was granted on June 15, 2018 with respect to 32,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments.